Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124577
Filing Date
2024-11-12
Accepted
2024-11-12 07:32:57
Documents
96
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bbio-20240930.htm   iXBRL 10-Q 4108479
2 EX-31.1 bbio-ex31_1.htm EX-31.1 25779
3 EX-31.2 bbio-ex31_2.htm EX-31.2 25899
4 EX-32.1 bbio-ex32_1.htm EX-32.1 11791
5 EX-32.2 bbio-ex32_2.htm EX-32.2 12055
  Complete submission text file 0000950170-24-124577.txt   17849677

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bbio-20240930.xsd EX-101.SCH 2759929
99 EXTRACTED XBRL INSTANCE DOCUMENT bbio-20240930_htm.xml XML 3321811
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38959 | Film No.: 241443327
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)